Next generation sequencing (NGS) of advanced PTCs has shown that aggressive tumor behavior and recurrence are more likely when more than one oncogenic mutation is present, especially when TERT promoter, TP53, PIK3CA and/or AKT1 mutations co-exist with BRAF V600E mutations (3, 12, 16, 17). This evidence concerns the gene BRAF and neoplasm.